Contents
Editor’s Letter
Editor’s introduction to the initial issue of the fifth volume of GaBI Journal
Letters to the Editor
First biosimilar of infliximab approved in Brazil: response from the Brazilian IBD society
Commentary
Low-cost generic drug programs in the US: implications for payers and researchers
Waiver of consent for retrospective chart review studies
Original Research
Review Article
Life begins at forty – hybridomas: ageing technology holds promise for future drug discoveries
Regulatory
Pricing of Biosimilars in Saudi Arabia
The EU is ready for non-biological complex medicinal products
Special Report
Complexity in the making: non-biological complex drugs (NBCDs) and the pharmacopoeias
Pharma News
Top developments in biosimilars during 2015